You are here

Article Text

Article menu
Download PDFPDF
4th Ovarian Cancer Consensus Conference
First-Line Therapy in Ovarian Cancer Trials
  1. Tate Thigpen, MD, PhD*,
  2. Andreas duBois, MD, PhD†,
  3. Jessica McAlpine, MD‡,
  4. Philip DiSaia, MD*,
  5. Keiichi Fujiwara, MD§,
  6. William Hoskins, MD∥,
  7. Gunnar Kristensen, MD,
  8. Robert Mannel, MD*,
  9. Maurie Markman, MD#,
  10. Jacobus Pfisterer, MD†,
  11. Michael Quinn, MD**,
  12. Nick Reed, MD†,‡,
  13. Ann Marie Swart, MD†,‡,
  14. Jonathan Berek, MD§§,
  15. Nicoletta Colombo, MD∥∥,
  16. Gilles Freyer, MD PhD¶¶,
  17. Dolores Gallardo, MD##,
  18. Marie Plante, MD‡,
  19. Andres Poveda, MD***,
  20. Lawrence Rubinstein, MD∥,
  21. Monica Bacon, RN†††,
  22. Henry Kitchener, MD†,‡ and
  23. Gavin C.E. Stuart, MD FRCSC‡
  1. * GOG;
  2. † AGO-OVAR, Germany;
  3. ‡ NCIC-CTG, Canada;
  4. § JGOG, Japan;
  5. ∥ NCI;
  6. NSGO, Scandinavia;
  7. # SWOG;
  8. ** ANZGOG, Australia/New Zealand;
  9. †† EORTC-GCG (Europe);
  10. ‡‡ MRC/NCRI, UK;
  11. §§ COGI;
  12. ∥∥ MaNGO, Italy;
  13. ¶¶ GINECO, France;
  14. ## GICOM, Mexico;
  15. *** GEICO, Spain; and
  16. ††† GCIG.
  1. Address correspondence and reprint requests to Tate Thigpen, MD, PhD, Division of Oncology, University of Mississippi School of Medicine, Jackson, MS 39216. E-mail: jtthigpen{at}att.net.

Abstract

At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients.

A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)?

A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials?

A3: Is the 2004 GCIG-recommended standard comparator arm still valid?

A4: What is the role of modifying dose, schedule, and delivery of chemotherapy?

A5: What role does surgery play today?

  • First line therapy
  • Ovarian cancer
  • Clinical trials

https://doi.org/10.1097/IGC.0b013e31821ce75d

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.